Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of benzenesulfonamide compound in preparation of medicine for treating acute kidney injury

A technology of acute kidney injury and benzenesulfonamide, applied in the field of biomedicine, can solve problems such as reducing the quality of life of patients, and achieve the effects of improving acute kidney injury and reducing morphological damage of kidney tissue.

Active Publication Date: 2021-09-21
XUZHOU MEDICAL UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the lack of effective drug therapy, renal replacement therapy is still the main measure for the current treatment of AKI, but this therapy will cause serious socioeconomic burden and reduce the quality of life of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of benzenesulfonamide compound in preparation of medicine for treating acute kidney injury
  • Application of benzenesulfonamide compound in preparation of medicine for treating acute kidney injury
  • Application of benzenesulfonamide compound in preparation of medicine for treating acute kidney injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Construction of cisplatin-induced acute kidney injury model in mice

[0029] 8-week-old C57BL / 6J mice were selected and randomly divided into two groups: SZ0232 administration group and normal saline group; the mice in the administration group were intraperitoneally injected with 0.5 mg / kg of SZ0232, and the mice in the normal saline group were given the same dose of physiological Saline was administered once a day for a week; subsequently, 20 mg / kg of cisplatin was administered intraperitoneally once, and SZ0232 or normal saline was continued at the same time, and the corresponding indicators were observed after 72 hours.

Embodiment 2

[0030] Example 2 Construction of mouse acute kidney injury model induced by ischemia-reperfusion

[0031] Select 8-week-old C57BL / 6J mice and randomly divide them into three groups: sham operation group + normal saline, ischemia-reperfusion + normal saline group, ischemia-reperfusion + SZ0232; kg of SZ0232, the mice in the normal saline group were given equal doses of normal saline, once a day, for one week continuously; then, the mice were anesthetized by intraperitoneal injection of 1% pentobarbital sodium (0.08ml / 10g). Ischemia-reperfusion group: Make an incision of 0.8-1.0 cm on each side of the back, find the renal pedicle and quickly block the right renal pedicle with a non-invasive micro arterial clip. After 50 minutes, the left kidney was resected after the left renal pedicle was ligated. The abdominal cavity was closed with layered sutures. After the operation, the mice were kept in an environment of 24-29°C, the vital signs of the mice were closely observed, and wa...

Embodiment 3

[0032] Embodiment 3 Biochemical Index Determination

[0033] Detection of BUN and SCr: Blood was collected before killing the mice, and centrifuged at 3000 g for 15 minutes. The separated supernatant serum was collected and operated according to the instructions (BUN detection kit from Nanjing Jiancheng Biotechnology Co., Ltd., SCr kit from Bioassays Systems).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a benzenesulfonamide compound in preparation of a medicine for treating and / or preventing acute kidney injury. The structural formula of the benzenesulfonamide compound is shown in the specification. The acute kidney injury is cisplatin or kidney ischemia reperfusion induced acute kidney injury. Experiments show that through administration of the benzenesulfonamide compound, the levels of BUN and SCr in serum of a mouse with acute kidney injury can be remarkably reduced, and the renal tissue form injury of the mouse with acute kidney injury can be remarkably relieved. The benzenesulfonamide compound has very important value for clinical prevention and treatment of acute kidney injury.

Description

technical field [0001] The invention relates to a medicine, in particular to the application of a benzenesulfonamide compound in the preparation of a medicine for treating and / or preventing acute kidney injury induced by cisplatin or renal ischemia-reperfusion, and belongs to the technical field of biomedicine. Background technique [0002] Acute kidney injury (acute kidney injury, AKI) is a clinical syndrome caused by a rapid decrease in renal function caused by various reasons in a short period of time, manifested by decreased glomerular filtration rate, creatinine, blood urea nitrogen retention, water electrolyte and Acid-base balance disorders, etc. AKI is a complex pathophysiological process, and various factors such as ischemia / reperfusion, application of surgical contrast medium, inappropriate medication, rhabdomyolysis, infection, etc. can lead to the occurrence of AKI. Among them, cisplatin and renal ischemia-reperfusion are important causes of acute kidney injury,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4015A61P13/12
CPCA61K31/4015A61P13/12
Inventor 钟丹丹胡成权玲玲孙莹
Owner XUZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com